Total Payments
$1.5M
2024 Payments
$162,931
Companies
37
Transactions
2,173
Medicare Patients
2,002
Medicare Billing
$187,114
Payment Breakdown by Category
Other$1.0M (69.9%)
Consulting$231,040 (15.9%)
Travel$143,914 (9.9%)
Food & Beverage$53,749 (3.7%)
Research$8,802 (0.6%)
Education$204.51 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $932,357 | 341 | 64.1% |
| Consulting Fee | $231,040 | 72 | 15.9% |
| Travel and Lodging | $143,914 | 509 | 9.9% |
| Honoraria | $83,543 | 33 | 5.7% |
| Food and Beverage | $53,749 | 1,198 | 3.7% |
| Unspecified | $8,802 | 10 | 0.6% |
| Education | $204.51 | 10 | 0.0% |
Payments by Type
General
$1.4M
2,163 transactions
Research
$8,802
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $338,057 | 420 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $152,278 | 227 | $0 (2024) |
| Shire North American Group Inc | $146,064 | 177 | $0 (2019) |
| Genentech USA, Inc. | $138,589 | 182 | $0 (2024) |
| Grifols USA, LLC | $102,102 | 91 | $0 (2024) |
| Pharming Healthcare, Inc. | $96,293 | 109 | $0 (2024) |
| GENZYME CORPORATION | $92,479 | 94 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $68,325 | 57 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $46,187 | 96 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $45,760 | 53 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $162,931 | 262 | AstraZeneca Pharmaceuticals LP ($67,557) |
| 2023 | $188,896 | 309 | AstraZeneca Pharmaceuticals LP ($49,992) |
| 2022 | $153,342 | 251 | AstraZeneca Pharmaceuticals LP ($30,770) |
| 2021 | $104,712 | 163 | AstraZeneca Pharmaceuticals LP ($24,742) |
| 2020 | $99,705 | 125 | Regeneron Healthcare Solutions, Inc. ($17,668) |
| 2019 | $258,698 | 345 | AstraZeneca Pharmaceuticals LP ($71,032) |
| 2018 | $248,875 | 342 | AstraZeneca Pharmaceuticals LP ($71,818) |
| 2017 | $236,451 | 376 | Shire North American Group Inc ($50,319) |
All Payment Transactions
2,173 individual payment records from CMS Open Payments — Page 1 of 87
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $54.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,544.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,398.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $118.55 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.34 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $597.93 | General |
| Category: GENETIC DISEASE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $92.46 | General |
| Category: GENETIC DISEASE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $41.00 | General |
| Category: GENETIC DISEASE | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $9.02 | General |
| Category: GENETIC DISEASE | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $7.84 | General |
| Category: GENETIC DISEASE | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $103.68 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $124.23 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $48.24 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $29.80 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $5.14 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $4.73 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $18.85 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $6,552 | 4 |
| Registry of Asthma Patients Initiating DUPIXENT (RAPID) | GENZYME CORPORATION | $1,500 | 4 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $750.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 526 | 3,423 | $119,215 | $50,163 |
| 2022 | 12 | 531 | 4,431 | $131,403 | $51,603 |
| 2021 | 11 | 493 | 3,450 | $102,962 | $46,187 |
| 2020 | 11 | 452 | 3,231 | $92,686 | $39,161 |
Total Patients
2,002
Total Services
14,535
Medicare Billing
$187,114
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 72 | $12,168 | $7,300 | 60.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 59 | 59 | $15,275 | $7,292 | 47.7% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 24 | 562 | $12,416 | $6,925 | 55.8% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 56 | 1,931 | $25,030 | $6,440 | 25.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 38 | 38 | $6,565 | $3,049 | 46.4% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 29 | 297 | $6,402 | $2,417 | 37.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 47 | 52 | $3,154 | $1,250 | 39.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 31 | 35 | $2,155 | $1,238 | 57.4% |
| 95115 | Injection of incremental dosages of allergen | Office | 2021 | 16 | 153 | $2,579 | $1,105 | 42.8% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 22 | 114 | $1,525 | $632.47 | 41.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 119 | 152 | $17,386 | $8,082 | 46.5% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2020 | 30 | 672 | $14,850 | $7,750 | 52.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 60 | 60 | $10,404 | $5,057 | 48.6% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2020 | 45 | 1,563 | $21,078 | $4,837 | 22.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 27 | 27 | $6,980 | $3,672 | 52.6% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2020 | 29 | 329 | $6,842 | $2,647 | 38.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 43 | 49 | $3,616 | $2,315 | 64.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 24 | $4,063 | $1,633 | 40.2% |
| 95115 | Injection of incremental dosages of allergen | Office | 2020 | 21 | 212 | $3,393 | $1,485 | 43.8% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 41 | 45 | $2,714 | $1,006 | 37.1% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2020 | 14 | 98 | $1,360 | $676.89 | 49.8% |
About Dr. Russell Settipane, MD
Dr. Russell Settipane, MD is a Allergy & Immunology healthcare provider based in Middletown, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053470476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Russell Settipane, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $162,931 received in 2024. These payments were reported across 2,173 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($932,357).
As a Medicare-enrolled provider, Settipane has provided services to 2,002 Medicare beneficiaries, totaling 14,535 services with total Medicare billing of $187,114. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Middletown, RI
- Active Since 12/08/2006
- Last Updated 07/18/2022
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1053470476
Products in Payments
- CINRYZE (Drug) $179,722
- DUPIXENT (Biological) $172,679
- FASENRA (Drug) $134,758
- Xolair (Biological) $130,216
- Xembify (Biological) $102,012
- RUCONEST (Biological) $96,293
- AIRSUPRA (Drug) $81,548
- DUPIXENT DUPILUMAB INJECTION (Biological) $73,364
- TEZSPIRE (Biological) $51,658
- FASENRA (Biological) $32,864
- CINQAIR (Drug) $31,484
- TAKHZYRO (Biological) $30,129
- DUPIXENT (Drug) $27,109
- NUCALA (Biological) $24,788
- Dymista (Drug) $14,581
- Orladeyo (Drug) $13,858
- STIOLTO RESPIMAT (Drug) $13,379
- SPIRIVA RESPIMAT (Drug) $13,048
- RINVOQ (Biological) $12,981
- Xhance (Drug) $12,930
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.